
According to Benzinga Pro data, during Q1, Global Blood Therapeutics (NASDAQ:GBT) posted sales of $55.16 million. Earnings were up 7.03%, but Global Blood Therapeutics still reported an overall loss of $81.42 million. Global Blood Therapeutics collected $56.10 million in revenue during Q4, but reported earnings showed a $87.58 million loss.